Johnson & Johnson - JNJ STOCK NEWS

Johnson & Johnson (NYSE: JNJ) announced an expansion of its partnership with the Biomedical Advanced Research and Development Authority (BARDA) to further develop its investigational COVID-19 vaccine. Janssen will invest approximately $604 million, while BARDA will contribute $454 million, supporting the Phase 3 ENSEMBLE trial with up to 60,000 volunteers. This collaboration emphasizes the importance of public-private partnerships in addressing the COVID-19 pandemic. J&J reaffirms its commitment to ethical vaccine development and adherence to scientific standards.

Johnson & Johnson will host a virtual Medical Devices Update on November 19, 2020, at 10 a.m. ET, showcasing innovations in digital surgery. The session will feature leadership insights, including those from Ashley McEvoy, and will cover the company's strategic positioning and advancements in Orthopaedics, Surgery, Interventional Solutions, and Vision franchises. Attendees can view franchise exhibits starting November 18, 2020, at 4:30 p.m. ET. Registration is available online, and a replay will be accessible post-event on the Investor Relations section of the JNJ website.

Johnson & Johnson (NYSE: JNJ) announced a cash dividend of $1.01 per share for the fourth quarter of 2020. This dividend will be paid on December 8, 2020 to shareholders recorded by the close of business on November 24, 2020. The ex-dividend date is set for November 23, 2020. This announcement reflects the company's commitment to returning value to its shareholders amidst its ongoing operations in the health care sector.

Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 results showing solid performance with reported sales of $21,082 million, a 1.7% increase from 2019. Net earnings surged 102.7% to $3,554 million, with diluted EPS at $1.33, reflecting a 101.5% growth. The Pharmaceutical segment grew 5.0%, leading overall growth, while Medical Devices faced a 3.6% decline impacted by COVID-19. New regulatory approvals and ongoing vaccine development were highlighted, showcasing the company's commitment to innovation.

Johnson & Johnson (NYSE: JNJ) announced an agreement with the European Commission to supply 200 million doses of its COVID-19 vaccine candidate to EU Member States, with the option for an additional 200 million doses. This follows ongoing discussions with stakeholders to improve global access to the vaccine. Johnson & Johnson plans to allocate 500 million doses for lower-income countries, starting mid-next year upon regulatory approval. The vaccine leverages AdVac technology, previously used in other vaccine candidates. The Phase 3 clinical trial is underway, evaluating a single-dose regimen.

Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion in cash. The tender offer for Momenta's shares was for $52.50 per share, with about 79.4% of shares tendered. The acquisition, effective October 1, 2020, allows Momenta to operate as a wholly-owned subsidiary, focusing on therapies for rare diseases and autoimmune disorders. The merger is anticipated to enhance patient care and facilitate multiple product launches in areas of significant unmet need.

Johnson & Johnson announced the initiation of its Phase 3 trial (ENSEMBLE) for the COVID-19 vaccine candidate, JNJ-78436735, after positive interim results from earlier studies. This pivotal trial aims to enroll 60,000 volunteers across multiple countries to assess the vaccine's safety and efficacy. The company plans to produce one billion doses annually, aiming for emergency use authorization in early 2021. The trial emphasizes diversity, including significant representation of vulnerable populations, and reflects J&J's commitment to transparency and collaboration with health authorities.

Johnson & Johnson (NYSE:JNJ) has announced its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion in cash. This strategic move aims to enhance Janssen's position in treating immune-mediated diseases, particularly through the lead asset nipocalimab, an anti-FcRn antibody. The acquisition is expected to provide global rights to nipocalimab, which could expand treatment options for autoantibody-driven diseases affecting 195 million individuals globally. The transaction is projected to close in the second half of 2020 and is anticipated to be modestly dilutive to JNJ's earnings in 2021.